The effect of Tlr4 and/or C3 deficiency and of neonatal gene therapy on skeletal disease in mucopolysaccharidosis VII mice

被引:7
作者
Xing, Elizabeth M. [1 ]
Wu, Susan [1 ]
Ponder, Katherine P. [1 ,2 ]
机构
[1] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA
关键词
Mucopolysaccharidosis; Toll-like receptor; Complement; Degenerative joint disease; Dysostosis multiplex; Gene therapy; ENZYME REPLACEMENT THERAPY; BETA-GLUCURONIDASE DEFICIENCY; JOINT DISEASE; MOUSE MODELS; FOLLOW-UP; EXPRESSION; MECHANISM; STORAGE; BONE; MANIFESTATIONS;
D O I
10.1016/j.ymgme.2014.12.305
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mucopolysaccharidosis (MPS) VII is a lysosomal storage disorder caused by the deficiency of the enzyme S-glucuronidase (Gusb(-/-)) and results in glycosaminoglycan (GAG) accumulation. Skeletal abnormalities include stunted long bones and bone degeneration. GAGs have been hypothesized to activate toll-like receptor 4 (Tlr4) signaling and the complement pathway, resulting in upregulation of inflammatory cytokines that suppress growth and cause degeneration of the bone. Gusb(-/-) mice were bred with Tlr4- and complement component 3 (C3)-deficient mice, and the skeletal manifestations of the doubly- and triply-deficient mice were compared to those of purebred Gusb(-/-) mice. Radiographs showed that purebred Gusb(-/-) mice had shorter tibias and femurs, and wider femurs, compared to normal mice. No improvement was seen in Tlr4, 0, or Tlr4/C3-deficient Gusb(-/-) mice. The glenoid cavity and humerus were scored on a scale from 0 (normal) to +3 (severely abnormal) for dysplasia and bone irregularities, and the joint space was measured. No improvement was seen in Tlr4, C3, or Tlr4/C3-deficient Gush mice, and their joint space remained abnormally wide. Gusb(-/-) mice treated neonatally with an intravenous retroviral vector (RV) had thinner femurs, longer legs, and a narrowed joint space compared with untreated purebred Gusb(-/-) mice, but no improvement in glenohumeral degeneration. We conclude that Tlr4- and/or C3-deficiency fail to ameliorate skeletal abnormalities, and other pathways may be involved. RV treatment improves some but not all aspects of bone disease. Radiographs may be an efficient method for future evaluation, as they readily show glenohumeral joint abnormalities. (C) 2014 Elsevier Inc All rights reserved.
引用
收藏
页码:209 / 216
页数:8
相关论文
共 49 条
[1]   Early Neurodegeneration Progresses Independently of Microglial Activation by Heparan Sulfate in the Brain of Mucopolysaccharidosis IIIB Mice [J].
Ausseil, Jerome ;
Desmaris, Nathalie ;
Bigou, Stephanie ;
Attali, Ruben ;
Corbineau, Sebastien ;
Vitry, Sandrine ;
Parent, Mathieu ;
Cheillan, David ;
Fuller, Maria ;
Maire, Irene ;
Vanier, Marie-Therese ;
Heard, Jean-Michel .
PLOS ONE, 2008, 3 (05)
[2]   Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation [J].
Baldo, Guilherme ;
Wu, Susan ;
Howe, Ruth A. ;
Ramamoothy, Meera ;
Knutsen, Russell H. ;
Fang, Jiali ;
Mecham, Robert P. ;
Liu, Yuli ;
Wu, Xiaobo ;
Atkinson, John P. ;
Ponder, Katherine P. .
MOLECULAR GENETICS AND METABOLISM, 2011, 104 (04) :608-619
[3]   VARIATION IN PHENOTYPIC EXPRESSION OF BETA-GLUCURONIDASE DEFICIENCY [J].
BEAUDET, AL ;
DIFERRANTE, NM ;
FERRY, GD ;
NICHOLS, BL ;
MULLINS, CE .
JOURNAL OF PEDIATRICS, 1975, 86 (03) :388-394
[4]   Therapy for Lysosomal Storage Disorders [J].
Beck, Michael .
IUBMB LIFE, 2010, 62 (01) :33-40
[5]   MURINE MUCOPOLYSACCHARIDOSIS TYPE-VII - CHARACTERIZATION OF A MOUSE WITH BETA-GLUCURONIDASE DEFICIENCY [J].
BIRKENMEIER, EH ;
DAVISSON, MT ;
BEAMER, WG ;
GANSCHOW, RE ;
VOGLER, CA ;
GWYNN, B ;
LYFORD, KA ;
MALTAIS, LM ;
WAWRZYNIAK, CJ .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (04) :1258-1266
[6]   Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA [J].
Circolo, A ;
Garnier, G ;
Fukuda, W ;
Wang, XF ;
Hidvegi, T ;
Szalai, AJ ;
Briles, DE ;
Volanakis, JE ;
Wetsel, RA ;
Colten, HR .
IMMUNOPHARMACOLOGY, 1999, 42 (1-3) :135-149
[7]   MUCOPOLYSACCHARIDOSIS TYPE-VII (BETA-GLUCURONIDASE DEFICIENCY) - A CHRONIC VARIANT WITH AN OLIGOSYMPTOMATIC SEVERE SKELETAL DYSPLASIA [J].
DEKREMER, RD ;
GIVOGRI, I ;
ARGARANA, CE ;
HLIBA, E ;
CONCI, R ;
BOLDINI, CD ;
CAPRA, AP .
AMERICAN JOURNAL OF MEDICAL GENETICS, 1992, 44 (02) :145-152
[8]   Anti-TNF-Alpha Therapy Enhances the Effects of Enzyme Replacement Therapy in Rats with Mucopolysaccharidosis Type VI [J].
Eliyahu, Efrat ;
Wolfson, Theodore ;
Ge, Yi ;
Jepsen, Karl J. ;
Schuchman, Edward H. ;
Simonaro, Calogera M. .
PLOS ONE, 2011, 6 (08)
[9]   Dose Responsive Effects of Subcutaneous Pentosan Polysulfate Injection in Mucopolysaccharidosis Type VI Rats and Comparison to Oral Treatment [J].
Frohbergh, Michael ;
Ge, Yi ;
Meng, Fanli ;
Karabul, Nesrin ;
Solyom, Alexander ;
Lai, Alon ;
Iatridis, James ;
Schuchman, Edward H. ;
Simonaro, Calogera M. .
PLOS ONE, 2014, 9 (06)
[10]   Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI [J].
Furujo, Mahoko ;
Kubo, Toshihide ;
Kosuga, Motomichi ;
Okuyama, Torayuki .
MOLECULAR GENETICS AND METABOLISM, 2011, 104 (04) :597-602